---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-283075"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:53:10.065045+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Q3 net loss $11.9M ($0.13/sh); advancing IKT-001 Ph2b in PAH

## Summary
- Net loss $11.9M for Q3 2025 vs $5.8M YoY; cash $77.3M at Sep 30, down from $97.5M at Dec 2024.
- R&D expenses $7.6M (Q3) vs $4.2M; includes $7.4M IPR&D write-off from CorHepta acquisition.
- Plans to initiate Phase 2b IMPROVE-PAH trial of IKT-001 in Q4 2025 (150 pts; 300/500 mg or placebo).
- Appointed Timothy Pigot as Chief Commercial and Strategy Officer.
- To present at Jefferies Global Healthcare Conference on Nov 17, 2025.

## SEC filing metadata
- accession: 0001193125-25-283075
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312525283075/0001193125-25-283075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312525283075/d93377d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-283075
- JSON: https://secwatch.observer/filing/0001193125-25-283075.json
- Plain text: https://secwatch.observer/filing/0001193125-25-283075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.